Guselkumab Shows Improvement in Inverse Psoriasis in Single Case Report

This publication presents a case report and literature review describing the use of guselkumab for inverse psoriasis in a single 48-year-old male patient. The patient received three subcutaneous injections of guselkumab, with follow-up at 12 weeks. The main reported outcome was a marked improvement in cutaneous lesions and pruritus. No specific effect sizes, absolute numbers, or statistical measures were provided for this improvement.

Safety and tolerability data were not reported for this case. The report did not mention any adverse events, serious adverse events, or treatment discontinuations. A comparator group was not included in this single-case description.

Key limitations stem from the study design. The evidence is from a single case report, which provides very low certainty. Generalizability is severely limited, and no conclusions can be drawn about causality, comparative efficacy, or the safety profile of guselkumab for this condition. Funding sources and author conflicts of interest were not reported.

In practice, this case suggests guselkumab may be a therapeutic option worthy of further investigation for inverse psoriasis. However, clinicians should interpret this as a preliminary signal only. Treatment decisions should be based on higher-quality evidence from controlled clinical trials.